Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

Stock Information for Jounce Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Jounce Therapeutics Inc.

Jounce Therapeutics Announces Closing of Tender Offer
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSI, HSKA, CVT, JNCE
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVT, USX, JNCE
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Jounce Therapeutics, Inc. (Nasdaq- JNCE) and Berkshire Grey, Inc. (Nasdaq- BGRY)
JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, MNTV, JNCE

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.